Media

Latest Blog Posts

  • 22 Apr, 2016

    Reducing Risk by Updating the Executive’s Dashboards

    By DLTA
    Executives and stakeholders in a drug development process are interested in two main things – seeing the overview of progress and having access to the budgetary data. Execs and stakeholders need this information to reduce risk during this lengthy process. If headway of the drug development process is stalled, halted or changes in any way the ...
    Read More
  • 08 Apr, 2016

    Creating the Collaborative Team through Enterprise Work Management

    By DLTA
    The overall success of a team depends on whether it functions as a whole. A collaborative team works together and communicates. Transparency of work lends itself to communication among team members and across teams. Communication should span from the CEO, to top executives, to lower ranks of employees. With transparency, nothing will be missed. Having continuous ...
    Read More
  • 01 Apr, 2016

    Eliminating-data-loss-by-reducing-risk

    By DLTA
    Many hands go into developing a new drug and it is over the course of several years. As a result, data winds up getting lost or work is duplicated. For pharmaceuticals and CROs, internal processes can be a challenge with information scattered among various divisions each with separate tracking systems. Developing a new drug and submitting ...
    Read More
  • 25 Mar, 2016

    Reducing Risk Through Enterprise Work Management

    By DLTA
    Bringing a new drug to market is not without risk. Certainly every pharmaceutical has completed rigorous analysis and determined acceptable risk tolerances for everything, from adverse events to re-submission delays. Even still, it is nerve racking making the decision to initiate new drug development research given the lengthy timelines and costs associated with a drug. ...
    Read More
  • 25 Mar, 2016

    Reducing-risk-in-the-drug-development-process

    By DLTA
    There are tremendous risks associated when developing a new drug. Ordinarily a drug lifecycle is between 10-12 years and teams are bound to encounter unforeseen hurdles. If teams are not utilizing the same processes and tracking their progress in the same way that can result in unforeseen delays and loss of data. It is critical that all ...
    Read More
  • 18 Mar, 2016

    Update-the-executives-dashboard

    By DLTA
    “Why do I have to keep updating the stakeholders? I just sent them a progress report a few days ago and nothing has changed…,” a question project managers ask themselves all too often. Obviously, the stakeholders have invested a significant portion of money into the development of the new drug and he/she is always in a ...
    Read More
  • 11 Mar, 2016

    Reduce-resubmissions-and-rework

    By DLTA
    The next big market share grab will go to the organization that figures out how to reduce the number of resubmissions to the Food and Drug Administration (FDA) , and thus reduce the time it takes to get a product to market. When you have a project on a large scale such as the development of ...
    Read More
  • 08 Mar, 2016

    Aurotech Attended the HIMSS Conference

    By DLTA
    Last week Aurotech attended the HIMSS 2016 conference in Las Vegas. Our purpose was to raise awareness for our company within the Health IT space. More than 50,000 people were in attendance. Including health IT professionals, clinicians, executives and vendors from around the world. An overwhelming number of people visited our booth. We featured both open ...
    Read More
Scroll Up